BioPharma Credit Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2017 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2017 - 2019
Net Income	122.18	108.45	182.31	84.96	89.14	Upgrade
Loss (Gain) From Sale of Assets	-	-	-	-	-9.46	Upgrade
Loss (Gain) From Sale of Investments	0.09	23.95	-5.95	23.75	-	Upgrade
Other Operating Activities	0	0.01	0.03	0.02	-21.76	Upgrade
Change in Accounts Receivable	-11.48	-0.48	-9.83	-9.8	16	Upgrade
Change in Accounts Payable	1.12	-8.74	17.71	-2.49	-15.84	Upgrade
Operating Cash Flow	111.91	123.18	184.28	96.44	58.07	Upgrade
Operating Cash Flow Growth	-9.15%	-33.15%	91.09%	66.06%	-55.84%	Upgrade
Investment in Securities	39.07	-1.66	48.19	-94.82	-47.47	Upgrade
Investing Cash Flow	39.07	-1.66	48.19	-94.82	-47.47	Upgrade
Repurchase of Common Stock	-105.75	-17.22	-50.09	-	-0.06	Upgrade
Common Dividends Paid	-109.02	-68.95	-95.74	-96.17	-96.17	Upgrade
Financing Cash Flow	-280.42	-106.99	-206.62	-100.16	-113.96	Upgrade
Foreign Exchange Rate Adjustments	-0	-0.01	-0.03	-0.02	-0.01	Upgrade
Net Cash Flow	-129.43	14.53	25.82	-98.56	-103.37	Upgrade
Levered Free Cash Flow	66.9	56.88	124.09	40.26	56.6	Upgrade
Unlevered Free Cash Flow	66.9	56.88	124.09	40.26	56.6	Upgrade
Change in Net Working Capital	9.47	10.91	-10.13	12.85	-0.89	Upgrade

Updated Sep 23, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.